Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment

Table 1

The clinical characteristics of patients who received SD-CCRT and BioRT.

Patient characteristic	SD-CCRT (𝑛=116)	BioRT (𝑛=54)	𝑃 value
Sex, number of patients (%)			0.933
Male	112 (96.6%)	52 (96.3%)
Female	4 (3.4%)	2 (3.7%)
Median age, y	55 (33∼74)	78 (46∼94)	0.000
Age			0.000
<70	111 (95.7%)	9 (16.67%)
≧70	5 (4.3%)	45 (83.33%)
Median follow-up time (m)	19.11 (2.67∼36.00)	13.05 (0.93∼36.00)	0.288
Smoking	42 (48.8%)	26 (54.2%)	0.592
Primary tumor site	38 (32.8%)	5 (9.3%)	0.000
Oral cavity	37 (31.9%)	15 (27.8%)
Oropharynx	37 (31.9%)	18 (33.3%)
Hypopharynx	4 (3.4%)	16 (29.6%)
Larynx
Stage			0.002
2	11 (9.5%)	12 (22.2%)
3	20 (17.2%)	16 (29.6%)
4a	72 (62.1%)	26 (48.1%)
4b	13 (11.2%)	0 (0.0%)
Induction chemotherapy			0.000
Yes	65 (56.0%)	8 (14.8%)
No	51 (44.0%)	46 (85.2%)

SD-CCRT: split-dose cisplatin-based concurrent chemoradiation therapy.
BioRT: cetuximab with concurrent radiation therapy.